Role of the Androgen Receptor in Human Breast Cancer

@article{Birrell2004RoleOT,
  title={Role of the Androgen Receptor in Human Breast Cancer},
  author={S. Birrell and R. E. Hall and W. Tilley},
  journal={Journal of Mammary Gland Biology and Neoplasia},
  year={2004},
  volume={3},
  pages={95-103}
}
Although the androgen receptor (AR)3is often co-expressed with the estrogen receptor (ER)and progesterone receptor (PR) in human breast tumors,its role in breast cancer is poorly understood. Specific growth stimulatory and inhibitory actions ofandrogens have been described in human breast cancercell lines. The mechanisms by which androgens exertthese contrasting growth effects are unknown. A commonly utilized second line therapy for the treatmentof advanced breast cancer is high… Expand
Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.
TLDR
The role of the AR in breast cancer is reviewed, potential avenues for the treatment of ER-/PR-/AR+ tumors with 'hormonal therapy' are discussed and exploration of new androgen-based hormonal therapy is warranted. Expand
Androgen Receptor-Targeted Therapy for Breast Cancer
TLDR
The role of AR across the differing subtypes of BC is discussed and the most recent clinical trial data for the use of androgen-directed therapy in the treatment of AR+ breast cancer is summarized, with a particular emphasis on TNBC. Expand
The role of the androgen receptor in triple-negative breast cancer
TLDR
AR-targeted therapy is one of the envisioned new therapies for TNBC; the therapeutic approach can involve the inhibition of androgen synthesis, use of non-androgenic AR-binding hormones, inhibition of co-regulators, activation of membrane AR, and reassessment of medroxyprogesterone acetate. Expand
Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
TLDR
Data suggest that reduced levels of AR or impaired AR function contribute to the failure of MPA therapy potentially due to abrogation of the inhibitory effect of AR on ER signaling. Expand
The Androgen Receptor in Breast Cancer: Biology and Treatment Considerations
TLDR
This review summarizes the recent progress made in understanding the role of the AR as a prognostic/predictive marker in breast cancer and the underlying mechanisms by which the androgen-signaling pathway may be involved in Breast cancer pathogenesis. Expand
Pushing estrogen receptor around in breast cancer.
TLDR
This review will focus on the established and emerging clinical evidence for activating PR or AR in ER-positive breast cancer to inhibit the tumour growth-promoting functions of ER. Expand
The Role of Androgen Receptor in Breast Cancer.
TLDR
The role of AR as a new important biomarker in breast cancer will be reviewed herein, with potential clinical benefit in both estrogen receptor(ER) positive and negative tumors. Expand
Triple-Negative Breast Cancer: Role of the Androgen Receptor
TLDR
The role of the AR in breast cancer tumorigenesis and current progress and future directions in the development of AR-targeted therapies are reviewed. Expand
Targeting the androgen receptor in prostate and breast cancer: several new agents in development.
TLDR
An overview of available agents which target the AR axis in both PCa and BCa is offered and insights into the novel drugs in development for targeting this signaling pathway are provided. Expand
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors
TLDR
It is demonstrated that mibolerone can have both androgenic and progestagenic actions in breast cancer cells, and high physiological doses of DHT reduced E(2)-mediated induction of the estrogen-regulated gene progesterone receptor (PR) to basal levels, and miboleranceone at lower doses eliminated PR expression, suggesting that mIBolerone may also act via the PR. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 91 REFERENCES
Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line.
TLDR
It is shown that androgens strongly suppress estrogen receptor (ER) and progesterone receptor contents in this model, as measured by radioligand binding and anti-ER monoclonal antibodies, and that the specific inhibitory effects of androgen therapy could be additive to the standard treatment limited to blockade of estrogens by antiestrogens. Expand
Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer.
TLDR
It is demonstrated that the progestins megestrol acetate and medroxyprogesterone acetate are strong competitors for steroids which bind specifically to androgen, glucocorticoid, and progesterone receptors, indicating that the PROGestins are able to bind to these receptors with high affinity. Expand
Androgens induce divergent proliferative responses in human breast cancer cell lines
TLDR
The results suggest that androgen action in breast cancer cell lines may not be solely mediated by binding of androgen to the AR and metabolites of DHT with oestrogenic activity, or androgen binding to receptors other than the AR, may explain the divergent responses to androgens observed in different breast cancercell lines. Expand
Interactions between Estrogens, Androgens, Progestins, and Glucocorticoids in ZR‐75‐1 Human Breast Cancer Cells
TLDR
It is found that all steroids that inhibit ZR-75-1 breast cancer cell growth stimulate the secretion and mRNA levels of gross cystic disease fluid protein-15, whereas estrogens have the opposite effects, thus suggesting that GCDFP-15 could well be a good marker for monitoring the response to androgens, progestins, and antiestrogens during the course of breast cancer therapy. Expand
MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression.
TLDR
MDA-MB-453 cells express high levels of functional AR, and thus provide a valuable in vitro model for further studies on androgen regulation of gene expression, and perhaps cell proliferation in breast cancer. Expand
Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells
TLDR
The present data indicate that the main action of MPA on ZR-75-1 human breast cancer cell growth is due to its androgen receptor-mediated inhibitory action, while its glucocorticoid-like activity could play an additional role at high concentrations. Expand
Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor
SummaryThis study demonstrates for the first time, that medroxyprogesterone acetate (MPA) inhibits the proliferation of the estrogen and progesterone receptor negative mammary cancer cell lineExpand
Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors
  • J. Isola
  • Biology, Medicine
  • The Journal of pathology
  • 1993
TLDR
The close association of AR with ER and PR suggests that immunohistochemical determination of androgen receptors may have value as a prognostic factor and/or predictor of response to endocrine therapy. Expand
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
TLDR
The continued expression of ER and/or PgR in many patients with tumor progression on tamoxifen indicates that mechanisms for resistance other than receptor loss are common in breast cancer. Expand
Characterization of progesterone receptor A and B expression in human breast cancer.
TLDR
In PR-positive breast tumors, the ratio of expression of PR-A and B proteins is close to unity, as is seen in a number of other progestin target tissues, but a significant proportion of tumors expressed very low levels ofPR-B and a consequently highPR-A/B ratio. Expand
...
1
2
3
4
5
...